InMed Pharmaceuticals (INM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
InMed Pharmaceuticals Inc. has reported a modest revenue increase and promising developments in their Alzheimer’s and dry AMD drug programs. With a revenue of $4.6M, marking an 11% increase from the previous fiscal year, the company is progressing with its INM-901 program for Alzheimer’s and INM-089 for dry AMD, suggesting potential future growth in its pharmaceutical pipeline.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
